A brand-new medication known as Tirzepatide was just approved by the Food and Drug Agency of the United States (Mounjaro is the brand name). When treating adults with type 2 diabetes, this medication is the first and only dual carbohydrate incretin polypeptide (GIP) receptor plus glucagon-like peptide-1 receptor activator (GLP-1 receptor agonist). It has been demonstrated that GIP can reduce the amount of food consumed and increase the energy expended, which helps with weight loss. Being a GIP & GLP-1 nicotinic receptor both has their benefits. When used together, GIP & GLP-1 receptor agonists can potentially significantly affect metabolic dysregulation.
Additionally, MounjaroTM, produced by Eli Lilly & Company, has been demonstrated to influence the management of obesity significantly. Doctors can prescribe this for weight control even though the FDA has yet to certify it for this purpose. Find out more information about this medication, including how it can help maintain weight loss.
Why Are The Obesity Doctors Excited About Mounjaro’s Weight Loss?
Clinical research on the Mounjaro weight reduction program reveals that individuals lost between 5% and 22.5% of their body weight during the study. Considering that persons who take several of the existing drugs for obesity that the FDA approves typically lose between 5 and 10% of their total weight, those are some amazing statistics.
In April of 2022, Eli Lilly disclosed the preliminary results of the SURMOUNT-1 clinical trial it had conducted. During the 72-week MounjaroTM (Tirzepatide) trial, people with surplus weight or obesity who had at least just one comorbidity (but not diabetes) used to have a weight reduction of up to 52 pounds, according to the findings of the study. Diabetes was not one of the comorbidities.
Tirzepatide caused a range of different dose-dependent weight losses. The participants in the study who took 5 milligrams of Mounjaro for weight loss saw an average weight loss of 35 pounds, equivalent to a 16% drop in their total body weight. Those who took a dose of 10 milligrams saw an average weight loss of 49 pounds, corresponding to a 21.4% reduction in total body mass. People who took Tirzepatide at the maximum dose of 15 milligrams shed an average of 52 pounds, equivalent to 22.5% of their body weight. But on the other hand, those who took the placebo lost only a few pounds, equivalent to losing 2.4% of their total body weight during the study.
In the randomized, double-blind study of the weight-loss drug, there were 2,539 participants from the United States, Brazil, Argentina, China, Japan, Mexico, India, Russia, and Taiwan. The participants’ mean body weight at the beginning of the study was 231 pounds.
Everyone who was randomly assigned to participate in the MounjaroTM (Tirzepatide) research started by receiving a dose of 2.5 mg once a week. After that, they proceeded through a phase called dose escalation, which consisted of increasing their dosage by 2.5 mg every 4 weeks until they achieved their desired level of 5, 10, and 15 mg.
Even though the Food and Drug Administration has given its approval for MounjaroTM (Tirzepatide) to be used in the treatment of type 2 diabetes, physicians who specialize in the treatment of obesity are especially excited about such a medication given the early findings of SURMOUNT-1.
How Can Taking Mounjaro (Tirzepatide) Assist With Weight Loss?
MounjaroTM (Tirzepatide), an injectable medication used once weekly, helps control blood sugar levels and may also assist in weight loss. This medication is similar to other GLP-1 medications.
There are two primary mechanisms through which GLP-1 receptor agonists facilitate weight loss. They slow down the rate at which the stomach empties, which allows you to feel full on a smaller amount of food. This helps lower calorie consumption while preventing you from feeling hungry. Second, the GLP-1 receptor agonists suppress the appetite, signal to the brain when it is full, and lessen the desire to eat unhealthy foods. Because of this, you can make dietary decisions that are more in line with your objectives.
The set point weight is the weight that your body strives to keep due to hormones, biology, & surroundings. The biological changes resulting from taking GLP-1 medications also may help reduce the set point weight. Because of this, Tirzepatide, along with other GLP-1 drugs like Ozempic, Saxenda, Trulicity, Rybelsus, and Victoza, has the potential to assist you in losing weight and maintaining your weight loss over the long term.
The fact that Tirzepatide is also effective on GIP receptors is one of the drug’s most interesting characteristics. GIP hormones cause the body to secrete insulin in response to the consumption of meals. However, low blood sugar levels increase glucagon secretion. Taking control of these processes helps encourage weight loss even further than what can be accomplished by taking GLP-1 medicines alone.
Is Mounjaro (Tirzepatide) FDA-Approved?
The use of MounjaroTM (Tirzepatide) to cure type 2 diabetes has been given the green light by the FDA. The manufacturer, Eli Lilly, is anticipated to submit an application to the FDA requesting clearance for an application for obesity. Novo Nordisk, the firm responsible for the production of Wegovy, utilized a comparable strategy. It was successful in obtaining FDA approval for such GLP-1 Ozempic (semaglutide) as a medication for type 2 diabetes before it was successful in obtaining FDA approval for the same medicine, but in different doses, for weight control.
Even though the FDA has not yet given its permission for Tirzepatide to treat obesity, there are some patients whom Found may be able to prescribe drugs like Mounjaro or weight loss before the FDA gives its approval for use in weight management.
What Adverse Reactions Have People On Tirzepatide Experienced?
The following are the adverse reactions that are most frequently seen with MounjaroTM (Tirzepatide):
- A Reduction In Appetite
- Stomach Irritation
Patients with a strong family history of malignant medullary tumors and who have Multiple Endocrine Neoplasia disorder type 2 are cautioned to use this medication with a boxed warning, as is the case with other GLP-1s. They must not take Tirzepatide for any treatment, even those intended to help them lose weight.
When It Comes To Weight Loss, What Is Found In Mounjaro?
There are diets for long-term weight loss. People who struggle with obesity can accomplish long-term weight loss also with the assistance of Found’s comprehensive toolset, which includes a variety of drugs and diverse treatment approaches. Our medical staff will evaluate a member’s healthcare requirements and recommend clinically appropriate treatments. These may include using Mounjaro to aid in weight loss or medication in the GLP-1 class.
Found provides a strategy for weight care backed by science focused on your particular biology, psychology, lifestyle, and the requirements of any prescription medications you take. Compared to participants in clinical studies who received the same medicine but also received behavioral change help from Found, Found members lost at least 13% extra weight and, in certain cases, upwards to 229% more weight than those participants in the clinical studies.
What Are The Effects Of Mounjaro On Weight Loss?
At the beginning of the trial, a total of 2,539 adults participated. On average, these participants weighed 231 pounds, and their body mass index (BMI) was 38. Obesity is defined as having a body mass index (BMI) of 30 or greater, and 95 percent of those surveyed had a BMI at least that high.
Participants were given a placebo injection once a week for a total of 72 weeks or one of three doses of tirzepatide: 5 milligrams (mg), 10 mg, or 15 mg. The dosages were randomly assigned.
People who took the highest dose dropped an average of 20.9 % of their body weight, equivalent to around 52 pounds, by the time the trial was over. When they took the 10 mg dose, they experienced an average weight loss of 19.5 percent, equivalent to about 49 pounds. When they took the 5 mg dose, they experienced an average weight loss of 15 percent, equivalent to about 35 pounds.
Most individuals experienced mild to severe adverse effects, the majority of which comprised gastrointestinal problems such as nausea, diarrhea, and constipation; approximately 4 to 7 percent of the respondents stopped receiving therapy due to drug-related adverse effects.
According to the findings of a recent trial, an injectable medicine that is administered once every week to treat type 2 diabetes may also have a high potential as a losing weight medication for those who are obese.
Participants who were overweight or obese and did not have type 2 diabetes and who took a medicine called Tirzepatide (offered as the diabetic treatment Mounjaro) had a loss of about 21 percent of the body weight on average when they took the maximum dose tested.
Researchers presented the study’s findings at the annual meeting of the American Diabetes Association (ADA) in New Orleans, and the study itself was published in The New England Journal of Medicine.